CD40 and neoplasm: Likewise, combination of CD40 agonist (FGK45) and gemcitabine induced tumor regression by targeting tumor-infiltrating macrophages involved in cancer inflammation in KPC mice (mutant KrasG12D and p53R172H) and human patients with pancreatic ductal carcinoma, since CD40 activation can disturb immune suppression and promote anti-tumor T cell response [228].